US 12336835
Neuromodulation to target glucose transporter and/or incretin pathways
granted A61PA61P1/16
Quick answer
US patent 12336835 (Neuromodulation to target glucose transporter and/or incretin pathways) held by GE Precision Healthcare LLC expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- GE Precision Healthcare LLC
- Grant date
- Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61P, A61P1/16